HPTN Publications

Mannheimer S, Wang L, Wilton L, Tieu HV, Del Rio C, Buchbinder S, Fields S, Glick S, Conor MB, Cummings V, Eshleman SH, Koblin B, Mayer KH . Infrequent HIV Testing and Late HIV Diagnosis Are Common Among US Black Men Who Have Sex with Men (BMSM). J Acquir Immune Defic Syndr. 2014, 67: 438-45

Maragh-Bass AC, Gamble T, El-Sadr WM, Hanscom B, Tolley EE . Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study. AIDS Care. 2021, 33: 1404-1413

Maragh-Bass AC, Gamble T, Tolley EE . 'Either You Float or You Drown:' The Role of Social Ties and Stigma in Lived Experiences of the HIV Care Continuum in HPTN 065. AIDS Behav. 2020, 24: 2532-45.

Margolick JB, Bream JH, Martinez-Maza O, Lopez J, Li X, Phair JP, Koletar SL, Jacobson LP . Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2017, 74: 407-417

Margolick JB, Bream JH, Nilles TL, Li H, Langan SJ, Deng S, Wang R, Wada N, Leng SX . Relationship Between T-Cell Responses to CMV, Markers of Inflammation, and Frailty in HIV-uninfected and HIV-infected Men in the Multicenter AIDS Cohort Study. J Infect Dis. 2018, 218: 249-258

Marzinke M, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, Clarke W . The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014, 10: 157-68

Marzinke MA, Clarke W, Wang L, Cummings V, Liu TY, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S, del Rio C, Magnus M, Mannheimer S, Fields SD, Mayer KH, Wheeler DP, Koblin BA, Eshleman SH, Fogel JM . Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis. 2014, 58: 117-20

Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho C, Cardozo N, Maia B, Khan T, Singh Y, Middelkoop K, Franks J, Valencia J, Sanchez N, Lucas J, Rooney JF, R . Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Lancet HIV. 2023, 10: e703-e712